(HealthDay News) – Less than half of newly diagnosed patients with type 2 diabetes achieve A1C <7%, and those that do achieve it more likely started with lower A1C levels, according to a study published in the March issue of Diabetes Care.
Gregory A. Nichols, PhD, from the Kaiser Permanente Center for Health Research in Portland, OR, and colleagues studied 1,139 patients with type 2 diabetes who initiated insulin therapy between January 2009 and June 2010.
The researchers found that mean A1C at insulin initiation was 8.2% in those who subsequently achieved A1C <7%, compared with 9.2% among those who did not. Within a mean of five months, 464 patients (40.7%) attained A1C <7%. When controlling for insulin regimen, dose, and oral agent use, preinsulin A1C was responsible for nearly all the explained variance in A1C change. Each one percentage point of preinsulin A1C reduced the probability of achieving A1C <7% by 26% (odds ratio, 0.74).
“Insulin initiation at lower levels of A1C improves goal attainment and independently increases glycemic response,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Merck Research Laboratories, which funded the study.